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Summary. Conventionally invitro cytotoxicity assays are 
performed as single-end-point determinations. To com- 
pensate for the diversity of growth rates among different 
cell lines in this report we describe acomputerized kinetic 
chemosensitivity assay based on quantification of bio- 
mass by staining cells with crystal violet. As a prerequisite 
four human breast cancer cell lines (MDA-MB-231, 
MCF-7, T-47-D and ZR-75-1) were characterized with 
regard to oestrogen and progesterone r ceptor content, 
modal chromosome number and proliferation kinetics 
depending on the number of passages in culture. With 
prolonged time in culture for ZR-75-1 exposed to various 
concentrations of cisplatinum a dose-related increase in 
drug effect was observed. Owing to a correction of the 
T/C values for the initial cell mass (at the time when drug 
is added) a sharp distinction between cytostatic and cy- 
tocidal drug effects becomes obvious in plots of corrected 
T/C values versus time of incubation. The influence of the 
untreated control on the corrected T/C values and pos- 
sible time courses of theoretical inhibition profiles (reflect- 
ing cytostatic, transient cytotoxic or cytocidal drug ef- 
fects as well as development of resistance) and their rela- 
tionship to the corresponding rowth curves of drug- 
treated cells are discussed. Chemosensitivity assays with 
diethylstilbestrol dipropionate, tamoxifen, melphalan, 
cisplatinum, vinblastine, Adriamycin and 5-fluorouracil 
prove the theoretical considerations tobe true for MDA- 
MB-231, MCF-7, T-47-D and ZR-75-1 human breast 
cancer cell lines in practice. 
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Introduction 
Within the drug-development programme of the National 
Cancer Institute (NCI) the models used to select new 
drugs for the clinic have changed periodically over the 
years (Venditti 1981; Goldin et al. 1979). Strategies have 
been based largely upon the in vivo testing of agents in 
mice bearing transplantable l ukemias and solid murine 
tumours. Such a screening system was composed of a 
highly sensitive "prescreen", the P388 leukemia model, 
and a "tumour panel" composed of three transplantable 
murine cancers, the L1210 lymphocytic leukemia, the 
B16 melanoma, and the M5076 sarcoma; and a human 
mammary tumour xenograft, he MX-1 (Venditti 1983). 
Since no perfect non-human model of human cancer 
could be found, most recently the NCI is implementing 
a new anticancer drug-screening programme using a dis- 
ease-oriented panel of cultured human tumour cell lines 
for the initial stages of screening (Shoemaker et al. 1985; 
Alley et al. 1988; Scudiero et al. 1988; Paull et al. 1989). 
This in vitro/in vivo concept differs from previous in vivo 
systems in two fundamental ways: (a) a single in vivo mu- 
rine leukemia "prescreen" step (P388) has been replaced 
by broad-based evaluation among a wide variety of cell 
lines; and (b) the major clinical forms of solid tumours 
are represented by panels of well-defined human tumour 
cell lines. Agents showing differential or selective pat- 
terns of in vitro growth inhibition will be evaluated sub- 
sequently in athymic mice bearing the same human tu- 
mour cell lines found sensitive in vitro. 
For the in vitro evaluation of antineoplastic agents on 
a wide variety of cultured tumour cell lines (Carmichael 
et al. 1987) microculture techniques are extensively in 
use, since "monolayer" methods probably offer the 
greatest flexibility in terms of possible drug exposure and 
recovery conditions. As a consequence the experimental 
protocols are very heterogeneous, depending on the spe- 
cial requirements and characteristics of a particular cell 
line under investigation. 
Vital parameters that vary between different assays in- 
elude: inoculum density, culture conditions, duration 
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of  drug exposure, duration of  the recovery period after 
drug exposure, and the nature o f  the end-point used to 
quantify drug effects (Alley et al. 1988; Scudiero et al. 
1988; Roper and Drewinko 1976; Finlay and Baguley 
1984; Reddel and sutherland 1987). Therefore inter- 
assay comparison, evaluation and interpretation of  drug 
action on the basis o f  median inhibitory concentrations 
(ICso values) f rom data collected among different cell 
lines are extremely difficult or impossible. 
In contrast o the MTT [3-(4,5-dimethylthiazol-2-yl)- 
2,5-diphenyltetrazolium bromide] assay, which is based 
on metabolic activity, the crystal violet technique mea- 
sures the total dye-binding capacity of  a given cell popu- 
lation, thus correlating with biomass. 
Since drugs can show quite different inhibitory effects 
dependent on the parameters mentioned above, a new ki- 
netic approach to chemosensitivity testing based on a 
standardized microculture crystal violet assay (Gillies et 
al. 1986; Kueng et al. 1989; Reile et al. 1990; Mtiller et al. 
1990) is presented in this publication. 
Materials and methods 
Chemicals. Reagents (A-grade purity) were obtained from Merck 
(Darmstadt, FRG). N-Hexamethylpararosaniline (crystal violet) 
was purchased from Serva (Heidelberg, FRG). The scintillation liq- 
uid Quickszint 212 was obtained from Zinsser Analytic (Frankfurt, 
FRG), N,N-dimethylformamide, spectrophotometric grade, from 
Aldrich (Steinheim, FRG). Fetal calf serum (FCS) and newborn calf 
serum (NCS) were from Gibco (Eggenheim, FRG). Millipore-fil- 
tered water was used throughout. 
Cell lines and routine culture conditions. All cell lines were obtained 
from the American Type Culture Collection (ATCC) (Rockvil!e, 
Md., USA). Cell line banking and quality control were performed 
according to the "seed stock concept" reviewed by Hay (1988). All 
culture media contained 50 mg/1 gentamycin (Sebio, Walehsing, 
FRG). 
MDA-MB-231 (ATCC no. HTB 26), a human adenocarcinoma 
of the breast (Cailleau et al. 1974), was maintained in McCoy's 5A 
medium (Boehringer, Mannheim, FRG) containing L-glutamine, 
NaHCO3 (2.2 g/l), and 10% NCS. 
The MCF-7 (ATCC no. HTB 22) human breast cancer cell line 
(Sou/e et al. 1973) was maintained inEagle's minimum essential me- 
dium (Sigma, Mfinchen, FRG) containing L-glutamine, NaHCO3 
(2.2 g/l), sodium pyruvate (Sigma, Mfinchen, FRG) (110 rag/l), and 
10% FCS. 
T-47-D (ATCC no. HTB 133) a human ductal adenocarcinoma 
of the breast, established from pleural effusion (Keydar et al. 1979), 
was grown in RPMI-1640 medium (Sigma, Miinchen, FRG) con- 
taining L-giutamine, NaHCOa (2.2 g/l), and 10% FCS. The culture 
medium was supplemented with 10 mg/1 bovine insulin (Sigma, 
Mfinchen, FRG). 
The ZR-75-1 (Engel et al. 1978) human breast cancer cell line 
(ATCC no. CRL-1500) was cultivated in RPMI-1640 medium (Sig- 
ma, Miinchen, FRG) containing L-glutamine, NaHCO3 (2.2 g/l), 
and 10% FCS. 
The cells were serially passaged weekly following trypsinization 
using trypsin (O.05%)/EDTA (0.02%) (Boehringer, Mannheim, 
FRG) and cultured in a water-saturated atmosphere of95% air and 
5% carbon dioxide at 37 ~ C in 75-cm 2flasks (Falcon Plastics 3023, 
Heidelberg, FRG). Cells were routinely monitored for, and shown 
to be free of, Mycoplasma contamination (Peters and Baumgarten 
1990). 
Growth character&tics. Proliferation kinetics and doubling times 
were determined by a computer-aided crystal violet procedure, 
which has been described recently (Reile et al. 1990). 
Cytogenetic analysis. The cells were grown to about 50 % confluence 
on microscopic slides. The slides were prepared as described else- 
where (Rooney and Czepulkowski 1986). In order to inhibit spindle 
formation, the slide chambers were inoculated with colcemid solu- 
tion (Serva, Heidelberg, FRG) to a final concentration f0.04 ~g/ 
ml and incubated for 3 h at 37 ~ C. The medium was removed by suc- 
tion and replaced with 0.075 M KC1. After 30 rain incubation at 
37 ~ C an equal volume of cold, freshly made fixative (absolute meth- 
anol/glacial acetic acid 3:1) was added. This hypotonic/fixative 
mixture was removed immediately and replaced twice with ice-cold, 
fresh fixative. The slides were removed from the dish and air-dried. 
The chromosomes were stained for 8 rain with 10 ml Giemsa stain 
plus 90 ml 0.025 M KH2PO4, pH 6.8. 
The chromosome number of 50 well-spread metaphases was de- 
termined using an Olympus BH-2 microscope with a 60 x SPlan- 
Apo (oil) objective (Olympus Optical Co. Ltd., Tokyo, Japan). 
The microscopic mage was focused through a NFK 2.5 • photo- 
eyepiece to a Panasonic FI0 CCD videocamera (Matsushita Com- 
munication I dustrial Co. Ltd., Osaka, Japan). For image analysis 
the video signal was transformed in a PIP-512/1024A video digitizer 
board (Matrox Electronic Systems Ltd., Quebec, Canada) installed 
in an Olivetti M24 personal computer (Ivrea, Italy) and visualized 
on a Sony PVM-1371 QM video monitor (Tokyo, Japan). The chro- 
mosomes were marked with a mouse and automatically counted us- 
ing an image-processing programme written in TURBO PASCAL. 
Oestrogen and progesterone r ceptor assay. Total cellular oestrogen 
receptor (ER) and progesterone receptor (PR) levels were measured 
simultaneously using a HPLC micromethod. The procedure de- 
scribed by Formento et al. (1987) was adopted with modifications 
(Birnbfck /988; v. Angerer et al. 1989). Confluent cultures (cells 
from three 75-cm 2flasks) were harvested with 0.02% EDTA and 
centrifuged at 1000 g for 10 min at 0 ~ C. After two cycles of washing 
with PBS (8.0g/1 NaC1, 0.2 g/1 KC1, 0.2 g/1 KHzPO4, 1.0 g/1 
Na~HPO 4. 2I-/20, 0.15 g/l NaH2PO4" H20) and centrifugation the 
cell pellet was shock-frozen and stored at - 80 ~ C. For cytosol prep- 
aration the pellets were resuspended in 0.5-1.0 ml phosphate-buf- 
fered saline (PBS). The cells were disrupted by sonication (10 bursts, 
step 5) (type G 15 sonifier; Branson Sonic Power Co., Danburg, 
Conn.) at 0 ~ C. Proteases were inhibited by the addition of 1 mM 
phenylmethylsulfonyl fluoride (Sigma, Miinchen, FRG). The com- 
pleteness of cell lysis was controlled by microscopic observation. 
For the simultaneous determination f ER and PR two solutions 
were prepared: (I) 18 nM Jail]R2858 (New England Nuclear, 
Dreieich, FRG), 18 nM [JH]QRG2058 (Amersham, Braunschweig, 
FRG), 3.6 txM cortisol, 3.6 IxM diethylstilbestrol (Sigma, Miinchen, 
FRG) in TEDG buffer, containing 10mM TRIS/HC1, 1 mM 
EDTA, 0.5 mM dithiothreitol (Sigma, M/inchen, FRG), 10 mM 
sodium molybdate, 20% (v/v) glycerol, pH7.4; (I1) 18riM 
[aH]R2858, 18 nM [JH]ORG2058, 3.6 ~M cortisol, 3.6/~M 
ORG2058 (Amersham Buchler, Braunschweig, FRG) in TEDG 
buffer. Incubation of aliquots of the cytosols with solution I reveals 
non-specific binding to ER and total binding to PR, whereas incu- 
bation with solution II reveals total binding to ER and non-specific 
binding to PR. Specific binding of each of the two different racers 
can be calculated by subtracting non-specific from total binding. 
The analysis was performed according to v. Angerer et al. (1989). At 
a flow rate of 1.0 ml/min (methanol/water, 80 :20 v/v) the t R inter- 
vals for [JH]R2858 were 2.7--4.3rain, for [3I-/]ORG2058 5.1- 
6.4 man and for [14C]oestrone (Amersham Buchler, Braunsehweig, 
FRG) 4.2-5.5 rain. 
Determination of cytosolic protein. Soluble protein was measured us- 
ing the bicinchoninic acid method described for microtitre plates 
(Smith et al. 1985; v. Angerer et al. 1989). 
Drugs. Cisplatinum (gold label) was obtained from Aldrich (Stein- 
heim, FRG). Melphalan, diethylstilbestrol dipropionate, tamoxifen 
(citrate salt) and 5-fluorouracil were purchased from Sigma 
(Miinchen, FRG), Adriamycin (doxorubicin hydrochloride with 
carrier lactose) and vinblastine (sulphate) from Serva (Heidelberg, 
FRG). Except for cisplatinum and melphalan, all drugs were dis- 
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solved in 70% (v/v) ethanol. Cisplatinum solution was prepared in 
dimethylformamide, m lphalan solution in 70% ethanol containing 
0.35% (v/v) hydrochloric acid. After appropriate dilution the drugs 
were added to culture medium such that the final ethanol concentra- 
tion was 0.07%, the final dimethylformamide concentration 0.1% 
(v/v). 
Chemosensitivity assay. The procedure described by Gillies et al. 
(1986) was modified and optimized for mieroculture conditions 
(Reile et al. 1990). For chemosensitivity testing the cells were seeded 
(100 lal/well) in 96-well flat-bottomed microtitration plates (Falcon 
Plastics 3075, Heidelberg, FRG) at an appropriate density of ap- 
proximately I5 cells/microscopic field (Leitz, Diavert, 320 x ). After 
48 h the medium was carefully removed by suction and replaced by 
fresh medium (200 Ixl/well) containing drugs (drugs were added as 
a 1000-fold concentrated stock solution) or pure solvent. On every 
plate the rows 5 and 6 (n = 16) served as controls, whereas two ver- 
tical rows (n = 16) per drug concentration were used. The cultures 
were not refed during chemosensitivity testing, since the exchange of 
the culture medium prolonged the lag phase of the cultures. How- 
ever, no influence on the growth characteristics caused by the prop- 
erties of the organic solvent (dimethylformamide and ethanol) was 
observed. After various times of incubation the culture medium was 
shaken offand the cells were fixed with 100 ~tl 1% glutardialdehyde 
in PBS/well for 15 min. The fixative was replaced by 150 ~tl PBS/well 
and the plates were stored in the refrigerator (4~ C). At the end of 
the experiment all trays were stained simultaneously with 0.02% 
aqueous crystal violet solution (100 p.1/well) for 30 min. Excess dye 
was removed by rinsing the trays with water for 15 rain. The stain 
bound by the cells was redissolved in 70% ethanol (180 p.1/well) 
while shaking the microplates for 2-4 h on a Krttermann 4010 
shaker (Krttermann, Hfinigsen, FRG). Absorbance was measured 
at 578 nm using a Biotek 309 Autoreader (Tecnomara, Fernwald, 
FRG). The readings were directly transferred to an Olivetti M 24 
(Ivrea, Italy) personal computer and saved on a diskette. 
Quantification of drug action. Corresponding absorbance measure- 
ments were identified, grouped according to the experimental l yout 
(usually n= 16/group) and corrected for outtiers at a confidence 
level of P=0.05. The confidence limits were adjusted according to 
[x~--XI <= 2"a(X) (1) 
where xi is the i-th value of the data set and Xis the mean of the data 
set. 
After the removal of outliers, the mean and standard eviation 
of grouped values were recalculated. Typical intraexperimental 
coefficient of variation (CV) values were found to be between 3% 
and 7%. Mean values that showed a CV > 10% were marked and 
excluded from further evaluation. 
Drug effects were expressed as corrected T/C values for each 
group according to 
(T/C)~o,(%)=AT--A~,o/A~-Ac,o" 100 (2) 
where A T is the mean absorbance of the treated cells, A~ the mean 
absorbance of the controls and Ac,o the mean absorbance at the 
time (t = 0) when drug was added. 
The significance of the corrected T/C values was verified by per- 
forming an analysis of variance based on the assumption of a t-dis- 
tribution (Sokal and Rohlf 1987). 
The variances of the T/C values were calculated from the known 
variances of the AT, A~ and A c,o values according to the general error 
law: 
Let 
f(AT,A~,A~,o) - (T/C)~orr. (3) 
Therefore, 
var(/) = (df/dAT) z. var(AT) + (df/dAJ. var(Ar 
+ (df/dAr z ~var(A~,o). (4) 
Results were printed in tabulated from ready for further evalu- 
ation (see Reile et al. 1990). 
Results 
Character&ation of the cell lines used in chemosensitivity 
studies 
Steroid receptor content. In addi t ion to rout ine micro-  
biological  and morpholog ica l  qual i ty control ,  oestrogen 
and progesterone receptor  contents, karyotype and 
growth characterist ics were per iodical ly  monitored.  
The steroid receptor  content of  the cell lines used are 
listed in Table 1. Both ER and PR concentrat ions differ 
substant ial ly among cell lines. Whereas MDA-MB-231 is 
clearly negative for both steroid receptors, the receptor 
content  of  MCF-7 ,  T-47-D and ZR-75-1 varies extremely 
with the passage. Short ly after rethawing, the ER concen- 
t rat ion of  MCF-7  cells (in passage 154) was at  the l imits 
o f  detection, whereas their PR  content was 39 fmol/mg. 
In passage 166 a drast ic increase in ER  (119 fmol /mg) 
with concomitant  decrease (8 fmol /mg) of  PR  was ob- 
served. Whereas the ER and PR contents of  ZR-75-1 in- 
creased with pro longed time in culture, for both ER and 
PR no trend was discernible in T-47-D. 
Table 1. Steroid receptor content of four human breast cancer cell 
lines in early plateau phase 
Cell line Passage Oestrogen a Progesterone a 
from receptor receptor 
origin (fmol/mg) (fmol/mg) 
MDA-MB-231 32 3 (2) 1 (1) 
37 2 (2) 7 (2) 
MCF-7 154 2 (2) 39 (9) 
166 119 (18) 8 (1) 
177 148 (13) 5 (2) 
T-47-D 90 22 (1) 1 (1) 
93 14 (10) 98 (4) 
96 8 (2) 37 (1) 
98 4 (i) 46 (1) 
109 22 (10) 69 (2) 
ZR-75-1 87 2 (1) 4 (1) 
89 2 (2) 0 
104 13 (2) 21 (9) 
fmol receptor/mg soluble protein; mean of three determinations 
(standard eviation in parentheses) 
Table 2. Karyology of four human breast cancer cell lines used in 
this study 
Cell line Passage Chromosome number 
from 
origin Modal Range 
MDA-MB-231 27 60 53-116 
36 60 55-185 
MCF-7 169 82 40-166 
T-47-D 98 64 58-115 
111 63 39-103 
ZR-75-1 92 74 27- 77 
130 75 33- 77 
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Genetic stability. Modal chromosome numbers and 
ranges for the human breast cancer cell lines in different 
passages are summarized in Table 2. 
Although differing from published values (Finlay and 
Baguley 1984), the modal chromosome numbers of 
MDA-MB-231, MCF-7 and T-47-D remained stable 
over the observed culture period. The modal chromo- 
some number (74-75) of the ZR-75-1 cell line is identical 
with the values reported for passage 38 in the original 
publication (Engel et al. 1978). In the case of severe struc- 
tural or numerical chromosome aberrations, cryopre- 
served stock cultures have to be used for further assays. 
Growth characteristics. Growth characteristics differ be- 
tween cell lines (Fig. 5). For MDA-MB-231 the minimal 
doubling time was 40 h, for MCF-7 45 h, for T-47-D 56 h 
and for ZR-75-1 84 h. 
Figure 1 illustrates how with prolonged time in culture 
the minimal doubling times may change in unpredictable 
ways (Finlay and Baguley 1984; Reile et al. 1990) even 
when inoculation density and culture conditions were 
kept constant. 
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F ig .  1. Variation of doubling time (TD) with the number of passage. 
The growth characteristics of MCF-7 controls (the culture medium 
contained 0.1% dimethylformamide) from different chemosensitiv- 
ity tests are shown. Culture conditions and the cell density of the in- 
oculum were identical. - - ,  155th; . . . .  , 169th; ..., 194th passage 
from origin 
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Kinetic crystal violet chemosensitivity assay 
Figure 2 summarizes the effect of 0.5, 1.0 and 5.0 pM cis- 
platinum on ZR-75-1 cells incubated for 333 h. After 
various times of incubation for six different end-points, 
the corrected T/C values were determined by the crystal 
violet procedure. Although a clear-cut dose/response r - 
lationship was observed for all end-points, it is apparent 
that the corrected T/C values continuously decreased 
with prolonged time in culture. Owing to the instability 
of cisplatinum under culture conditions (full activity re- 
tained for 6 h; complete loss at 48 h; Wilson 1986), the 
changes in T/C . . . .  primarily do not seem to be directly re- 
lated to drug incorporation during prolonged time of 
treatment. 
Figure 3 shows a diagrammatic representation f  typi- 
cal data obtained by the kinetic crystal violet chemosen- 
sitivity assay based on the determination f the reproduc- 
tive potential of a drug-treated culture. The relationship 
between growth kinetics of treated cell populations on 
one hand, and a plot of corrected T/C values versus time 
of incubation on the other, is illustrated in Fig. 3 A, B. In 
the following, drug effects are presented as plots of cor- 
rected T/C values versus time of incubation. The correc- 
tion for the initial cell number (at the time when drug is 
added) allows discrimination between cytostatic and cy- 
tocidal drug action at any time of incubation. 
Differential chemosensitivity 
of the human breast cancer cell lines MDA-MB-231, 
MCF-7, T-47-D, and ZR-75-1 
to selected anti-tumour agents 
Since there was no significant difference between dimeth- 
ylformamide and ethanol, only the growth characteristics 
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Fig. 2. Inhibitory effect of cisplatinum on the proliferation of human 
ZR-75-] breast cancer cells as a function of incubation time deter- 
mined by the crystal violet assay. Cells in passage 93 were treated 
with (n) 0.5 ~tM (o) 1 ~tM and (o) 5 IxM cisplatinum 
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Fig. 3. Schematic diagram of the interrelationship between growth 
curves (A) and corrected T/C profiles (B) illustrating the in vitro re- 
sponse of cells to treatment with chemotherapeutics. C, Prolifer- 
ation kinetics of the untreated control. 1, The population com- 
pletely recovers after initial damage (cytotoxic drug effect). 2, Cell 
proliferation isinhibited (cytostatic drug effect). 3, The profiles re- 
present the disintegration fthe cells (cytocidal drug effect) 
2.0 
1.5 
A578 
1.0 
0.5 
200 
1.50 
TD[h] 
100 
C 
I I I 
[] 
A 
I I I 
100 200 300 
TIME OF INCUBATION [h] 
i\ \ 
\ 
\ 
\ 
\ 
\ 
\ 
\ 
\ 
I t I I 
i 
i .: 
I " / 
/ ,," /-- 
t / 
i / / ." / 
i / \ ...," / /  
""-/~ ._..-'S " /  
"~ / ,,.'" 
B 
0 I I I I 
50 I00 150 200 250 
TIME OF INCUBATION [hi 
Fig. 4 A, B. Growth characteristics of the untreated controls (culture 
medium contained 0.07% ethanol) from the following chemosensi- 
tivity assays. In order to obtain higher esolution time intervals are 
closely scattered. Therefore, in all experiments in addition to the ob- 
ligatory controls on every microtitration plate (rows 5 and 6) several 
microplates were incubated under control conditions. At the time 
points indicated the cells were fixed with glutardialdehyde and pro- 
cessed simultaneously with the trays from the chemosensitivity as- 
say at the end of the experiment. From these control growth curves 
and the data from the corresponding corrected T/C profiles any 
growth curve of a drug-treated cell population can be reconstructed 
according to Eq.2. A Growth curves, rn T-47-D, passage 105; I ,  
ZR-75-1, passage 93; o, MDA-MB-231; passage 35; o, MCF-7, pas- 
sage !68. B Corresponding doubling times (To) as a function of in- 
cubation time .... , T-47-D, passage 105; - - - ,  ZR-75-1, passage 93; 
- - ,  MDA-MB-231, passage 35; - - - ,  MCF-7, passage 168 
of the controls containing the vehicle ethanol are 
depicted in Fig. 4. 
According to Eq. 2, any growth curve of a drug- 
treated cell population can be reconstructed from the T/ 
C .... profile (Figs. 5-8) and the growth curve of the cor- 
responding control (Fig. 4 A). 
Response to hormonal therapy. None of the breast cancer 
cell lines investigated was inhibited by 10 nM diethylstil- 
bestrol (Fig. 5 A). On the contrary, cell proliferation of 
MCF-7, T-47-D and ZR-75-1 was stimulated to a certain 
extent. Stimulation became obvious after about 100 h of 
incubation. This effect (167% T/C . . . .  for ZR-75-1 after 
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Fig.SA, B. In vitro effect of hormonal therapy on human breast 
cancer cell lines. [], T-47-D, passage 105; m, ZR-75-1, passage 93; o, 
MCF-7, passage 168. A 10 nM diethylstilbestrol dipropionate. B
0.5 ~tM tamoxifen; MDA-MB-231 was not influenced by tamoxifen 
concentrations up to 10 ~tM 
189 h) was transient. At the end of the assay all cell lines 
regained a T/C .... value of about 100%. Figure 5 B shows 
the effect of 0.5 pM tamoxifen. MCF-7, T-47-D and ZR- 
75-1 were inhibited with a minimal T/Ccor~ value of 
around 40%. As discussed for curve 1 in Fig. 3, all three 
cell lines recovered towards the end of the experiment. 
Cell proliferation of MDA-MB-231 was not affected by 
tamoxifen concentrations up to 10~tM (data not 
shown). 
Sensitivity to alkylating agents. The effect of 1 ~tM mel- 
phalan and 1 ~tM cisplatinum is shown in Fig. 6A, B. 
Dramatic differences in sensitivity to melphalan were de- 
tectable. ZR-75-1 was transiently stimulated and a final 
T/Ccorr of 89% was reached after 333 h of incubation. 
Melphalan was cytostatic to MDA-MB-231 and MCF-7 
whereas T-47-D regained proliferative integrity after 
slight initial impairment by 1 ~tM melphalan. 
Cisplatinum (1 ~tM) was cytostatic to ZR-75-1 and 
MCF-7. MDA-MB-231 and T-47-D recovered after ini- 
tial damage. 
Sensitivity to naturalproducts. Chemosensitivity to I nM 
vinblastine is presented in Fig. 7 A. Although initially in- 
hibited by the alkaloid, ZR-75-1 recovered (cf. Fig.3, 
curve 1) with a T/C .... value of around 60%. For T-47-D 
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Fig.6A, B. Chemosensitivity of human breast cancer cell lines 
against alkylating agents, n, T-47-D, passage 105; u, ZR-75-1, pas- 
sage 93; o, MDA-MB-231, passage 35; O, MCF-7, passage 168. A 
1 gM melphalan; B 1 gM cisplatinum 
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Fig.7A, B. Chemosensitivity of human breast cancer cell lines 
against natural products, rn, T-47-D, passage 105; i,  ZR-75-1, pas- 
sage 93; o, MDA-MB-231, passage 35; o, MCF-7, passage 168. A 
1 nM vinblastine; B 1 IxM Adriamycin 
the TIC . . . .  curve showed a similar time course but the in- 
hibitory effect of vinblastine was less pronounced, and 
the culture recovered almost completely. Likewise MDA- 
MB-231 and MCF-7 were initially inhibited. The trend of 
the graphs to parallel the time axis while the correspond- 
ing controls (cf. Fig. 4 A) still exhibit relatively high pro- 
liferation rates indicates the tendency of the cultures to 
recover. Vinblastine at 0.1 IxM was cytocidal to MCF-7, 
ZR-75-1 and T-47-D and cytostatic to MDA-MB-231 
(data not shown). 
Adriamycin (1 gM, see Fig. 7 B) was cytocidal to all 
four cell lines (data for MDA-MB-231 are not shown). 
Effect of the antimetabolite 5-fluorouracil. At 1 gM, 5- 
fluorouracil (Fig. 8) exerted a cytostatic effect on ZR-75- 
1 and T-47-D. In comparison to cisplatinum (Fig. 6 B) the 
manifestation of drug action was delayed. Cell prolifer- 
ation of MDA-MB-231 and MCF-7 was only slightly af- 
fected. 
Discuss ion  
The presence of measurable amounts (usually > 10 fmol/ 
mg cytosolic protein) of both ER and PR is associated 
with the highest response rate to hormonal treatment. 
Turnours lacking both receptors rarely respond. ER- 
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Fig. 8. Effect of 1 laM 5-fluorouracil on the human breast cancer cell 
lines: n, T-47-D, passage 105; u, ZR-75-1, passage 93; o, MDA- 
MB-231, passage 35; o, MCF-7, passage 168 
positive tumours that recur following hormonal manipu- 
lation tend to have low or absent ER levels (Canellos 
1985). Spontaneous evolution of several distinct sublines 
and clones of T-47-D with marked ifferences in ER and 
PR contents under identical culture conditions has been 
reported recently (Reddel et al. 1988). 
Owing to this dramatic variability, periodical control 
of the steroid receptor state (ideally parallel to chemosen- 
sitivity testing) is essential. 
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Since ER is heterogeneously distributed in different 
cell clones of a breast umour, the additional semiquanti- 
tative immunohistochemical determination and intracel- 
lular localization of the receptor could be useful. 
To overcome the problem of genetic instability of tu- 
mour cells (Whang-Peng et al. 1983; Yunis 1983) in test- 
ing anticancer drugs by cell culture techniques, chromo- 
some analysis is indispensable. 
The determination of growth kinetic curves by the 
crystal violet method is very easy to perform, because - 
compared to the tetrazolium-based assay - immediate 
and complete processing and measurement of the micro- 
plates after various times of incubation are not essential. 
For an optimal design of chemosensitvity assays the 
knowledge of the beginning and duration of the logarith- 
mic growth phase is essential. This can be easily obtained 
from a diagram plotting the doubling time versus the time 
of incubation where, under these conditions, the graph 
parallels the x-axis. 
Although it is generally claimed that chemosensitivity 
testing is performed with exponentially growing popula- 
tions it must be pointed out that for all cell lines exam- 
ined, the exponential growth phase is restricted to maxi- 
mally two generations. Exponentiality assumes that the 
growth rate and doubling time are both fixed constants, 
a situation that is rarely encountered either in vivo or in 
culture (Skehan 1986). In fact, most mammalian cells in 
culture exhibit nonexponential growth, i.e. the growth 
rate and doubling time change continuously (Skehan and 
Friedman 1984; Reile et al. 1990), and there is no single 
value of either that can be used to characterize the growth 
of a system. Although Freshney et al. (1975) previously 
indicated that IC50 values are influenced by the density 
of plated cells and decrease continuously with increasing 
time of drug exposure, thus reflecting an increase in drug 
sensitivity, still most chemosensitivity assays are per- 
formed as single-end-point determinations (Skehan et al. 
1990; Rubinstein et al. 1990). Whereas an increase in the 
duration of the exposure to a drug frequently increased 
the sensitivity, no change or decrease in chemosensitivity 
occurred with time in culture. The alterations observed 
are caused, on the one hand, by specific properties of 
the drugs and, on the other hand, by the nature of the as- 
say used to quantify the drug effect. 
Cytotoxicity assays measure drug-induced alterations 
in metabolic pathways (MTT assay) or structural integ- 
rity (e.g. 51Cr release or dye exclusion), which may or 
may not be directly related to cell death. In contrast, sur- 
vival (reproductive integrity) assays measure the end re- 
sult of such metabolic perturbations, which may lead 
either to cell recovery or cell death. 
Conventionally drug effects are compared on the basis 
of uncorrected T/C (or resulting IC5o) values, which 
means that the initial cell density (at the time when drugs 
are added) is not taken into account. Especially when al- 
terations of A578 are small compared with the absor- 
bance of the initial cell density, this practice results in 
pronounced underestimation f inhibitory drug effects. 
The correction of the T/C values has the advantage that 
only net changes in biomass are evaluated. As a con- 
sequence, inhibitory effects can be clearly distinguished 
from cytocidal drug action. 
The time course of the growth curve of the untreated 
control is of extreme importance because of its direct in- 
fluence on the T/C values. Therefore, its determination 
with precise discrimination between the lag, log, and 
plateau phases is a must. 
T/C .... decreases as long as the treated cells (T) grow 
more slowly than the untreated control (C). While the 
control cells enter the plateau-phase asgrowth comes to 
a standstill, T/C . . . .  stagnates or increases. 
When the absorbance of the treated cells remains un- 
changed (cytostatic drug effect), as shown in curve 2, T/ 
C .... is characterized by a steep initial decrease until a 
constant value, determined by the absorbance of the 
treated cells and the absorbance ofthe controls at satura- 
tion density, is reached and maintained. 
The effects of cytotoxic substances may appear in dif- 
ferent ways, for example, when the culture is toxically 
damaged shortly after the addition of the drug but during 
the course of the experiment completely recovers, i.e. it 
regains full reproductive integrity and finally reaches the 
saturation density of the untreated control (curve 1). Pos- 
sible reasons for such behaviour (depending on the par- 
ticularities of the tumour cell line and the biochemical 
target of the drug) are: 
1. Inactivation of the drug in the culture medium or me- 
tabolism into less active compounds 
2. Only a fraction of the cell population being killed; the 
non-lethally damaged (metabolic impair) population re- 
covers 
3. Development of secondary resistance. 
In all cases, T/Cr continuously decreases as long as 
C grows faster than T and remains constant when the 
proliferation rates of T and C are identical. The following 
increase in T/C .... is caused by a relative acceleration of 
cell proliferation of T compared to C, which enters the 
plateau phase. When enough time of incubation is pro- 
vided, a final T/C .... of 100% will be obtained as soon as 
T reaches the saturation density of C. 
On the other hand, the exposure of tumour cells to 
toxic agents (curve 3) may result in cell death accompa- 
nied by cell lysis (cytocidal drug effect). As cells die, the 
absorbance of the treated culture wells is lower than the 
absorbance of the culture at the time when drug was 
added. Since the initial absorbance is subtracted, T/Ccorr 
becomes negative when the lysing cells outnumber the 
proliferating cell population. As long as the plateau 
phase is not reached by C, T/Cooer increases for arithmetic 
reasons. The final numerical value is determined by the 
absorbance of T and C corrected for the initial cell mass. 
A second intersection of the T/C~o~r versus time graph 
with the time axis is usually not observed. A transition of 
the curve from negative to positive values theoretically 
indicates revival of the culture. 
Although the plot of the corrected T/C values versus 
time clearly represents cytocidal drug action, the cor- 
rected T/C ratio is not appropriate for precisely quantify- 
ing net cell killing. When the absorbance of treated cells 
(AT) is less than that of the culture at t = O (A~,0) the ex- 
tent of cell killing must be calculated as 100- (AT -- A~,o/ 
Ar o (cf. Skehan et al. 1986). 
This specific assay is applicable to any adherently 
growing cell type and allows for a quantitative compari- 
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son of structural drug analogues, as well as alternative ex- 
perimental dosage formulations. 
Figures 5-8 clearly demonstrate that the theoretical 
considerations discussed in Fig. 3 are proved true in prac- 
tice. This study emphasizes the great variation in the in- 
trinsic responses of cell lines to a group of clinically used 
agents as a function of incubation time. To compensate 
for the diversity of growth rates among different cell 
lines, in our opinion a kinetic approach to chemosensitiv- 
ity testing should be sought. Although for preliminary 
large-scale screening single-end-point determinations 
may be sufficient, for more detailed investigations of 
drug action the kinetic assay procedure is preferable be- 
cause it provides unambiguous information concerning 
differential sensitivity and, in addition, potential devel- 
opment of resistance is readily observed from one single 
experiment. 
In order to improve in vitro/in vivo correlation, 
chemical stability and pharmacokinetic parameters (con- 
centration of free drug and time of exposure) of the drugs 
to be tested should be taken into account. The choice of 
drug concentrations should be dictated by considerations 
of the therapeutic levels that can be achieved with clini- 
cally used drug dosages dependent on scheduling. The ki- 
netic approach presented in this publication offers the 
great advantage of combining and coordinating a variety 
of different antitumour drugs (new and clinically estab- 
lished) according to their inhibition (T/C .... versus time) 
profiles. 
This method, particularly developed for the in vitro 
evaluation of the activity of potential anticancer drugs, 
incorporates the desirable features of simplicity, repro- 
ducibility and sensitivity. The kinetic assay procedure can 
be easily adopted to the sulphorhodamine B procedure 
currently favoured by the NCI  (Skehan et al. 1990; Ru- 
binstein et al. 1990). 
In our opinion, the application of this kinetic assay to 
compounds (selected by conventional screening) could be 
of great value in revealing specific properties of drugs or 
special peculiarities of different umour types, resulting in 
improved predictibility of in vivo drug effects. 
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